Theralink Technologies provides personalized medicine data through its Theralink assays, initially for breast cancer, to assist the treating physician in a data-driven process for treatment decision support and potentially enable new predictive biomarker-based patient selection. Theralink is the leading developer of phosphoproteomic technologies for measuring the activation state of key drug targets and signaling pathways, with applications across multiple cancer types, including breast, non-small cell lung, ovarian, liver, prostate, gastric, brain, kidney, colorectal and pancreatic. Theralink was developed to empower physicians with potentially actionable information missed entirely by genomics assays to help them make time-sensitive treatment decisions for their patients. Theralink was designed to provide new predictive biomarkers through the direct measurement of drug target activation mapping, making Theralink instrumental in the development of molecular targeted therapies. The information gathered through measurement of protein and phosphoprotein markers has the potential to help physicians make molecularly rationalized treatment decisions that could improve treatment outcomes and reduce side effects by foregoing ineffective therapy.
KCSA Strategic Communications
Valter Pinto and Allison Soss
420 Fifth Avenue New York NY 10018
T: (212) 896-1254